MedPath

Foot/Hand Neuromodulation for Overactive Bladder (OAB)

Not Applicable
Terminated
Conditions
Overactive Bladder
Interventions
Device: Foot stimulation
Registration Number
NCT01972061
Lead Sponsor
Christopher J Chermansky, MD
Brief Summary

The purpose of this study is to determine if electrical stimulation of the foot is effective in the treatment of overactive bladder conditions.

Detailed Description

Foot neuromodulation is designed to treat OAB conditions by electrically stimulating the somatic afferent nerves in the foot using skin surface electrodes. The foot stimulation is non-invasive, can be performed at home, and has no adverse effects. Foot neuromodulation therapy will likely be accepted by more patients and have the potential to make a broader impact on the improvement of OAB conditions.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
44
Inclusion Criteria
  1. 18 year old men and women and older
  2. Currently having overactive bladder (OAB) symptoms, i.e. urgency, frequency, or incontinence
  3. No evidence of neurological disorder or urinary tract infection, i.e. clinically diagnosed as idiopathic OAB
Exclusion Criteria
  1. Pregnant women in their late pregnancy phase will be excluded because the increasing size of the baby/uterus may cause overactive bladder.
  2. Patients with implanted electrical stimulators such as pacemaker will be excluded for potential interference with the TENS stimulator.
  3. Patients who are allergic to Cipro or Bactrim will be excluded from the CMG study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
3 hour hand groupFoot stimulationHand stimulation will be applied daily for 3 hours in the evening.
CMG groupFoot stimulationFoot stimulation will be applied during a cystometrogram (CMG).
3 hours groupFoot stimulationFoot stimulation will be applied daily for 3 hours in the evening.
1/2 hour groupFoot stimulationFoot stimulation will be applied daily for 1/2 hour in the evening.
Primary Outcome Measures
NameTimeMethod
Number of Urinary Incontinence Episodes Per DayWeek 1, Week 2, Week 3

Participants kept a daily voiding diary during week 1 (baseline), week 2 (foot stimulation), and week 3 (post foot stimulation). The average number per day urinary incontinence episodes was calculated for week 1 and week 2 for each subject.

Secondary Outcome Measures
NameTimeMethod
Number of Urinary Urgency Episodes Per DayWeek 1, Week 2, Week 3

Participants kept a daily voiding diary during week 1 (baseline), week 2 (foot stimulation), and week 3 (post foot stimulation). The average number per day urinary urgency episodes was calculated for week 1 and week 2 for each subject.

Trial Locations

Locations (1)

University of Pittsburgh

🇺🇸

Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath